Exposure–Response Analyses for the MET Inhibitor Tepotinib Including Patients in the Pivotal VISION Trial: Support for Dosage Recommendations Cancer Chemother Pharmacol. 2022 Jul;90(1):53-69. Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R. JournalMIDDOncologyPharmacometrics Pharmetheus Affiliates Principal Consultant, Client Operations Manager Sofia Friberg Hietala See bio Chief Technology Officer Joakim Nyberg See bio
